SCM LifeScience Co

SCM LifeScience Co Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of SCM LifeScience Co (298060.KQ) as of Oct 15, 2026 is -0.16. In the previous year, Net Debt to Free Cash Flow Ratio was 0.07 — a change of -339.39% (lower).

Net Debt/FCF

-0.16

YoY

-339.39%

Last updated:

Net Debt to Free Cash Flow Ratio of SCM LifeScience Co is 2024 -0.16 . Net Debt to Free Cash Flow Ratio of SCM LifeScience Co was 2023 0.07 . It decreases by -339.39% lower compared to the previous year.

The SCM LifeScience Co Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2017
-0.56 KRW
Jan 1, 2018
2.00 KRW
Jan 1, 2019
0.90 KRW
Jan 1, 2020
2.26 KRW
Jan 1, 2021
1.34 KRW
Jan 1, 2022
0.10 KRW
Jan 1, 2023
0.07 KRW
Jan 1, 2024
-0.16 KRW
The SCM LifeScience Co Net Debt/FCF history
YEARNet Debt/FCFYoY
-0.16-339.39%
0.07-36.90%
0.10-92.25%
1.34-40.95%
2.26+151.54%
0.90-54.96%
2.00-458.29%
-0.56—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCM LifeScience Co Stock analysis

What does SCM LifeScience Co do? SCM LifeScience Co Ltd is a biotechnology company headquartered in Incheon, South Korea. The company focuses on the development and production of cell therapy products, including adult stem cell therapies. It also engages in agency testing for cell production and quality assurance, as well as providing adult stem cell consulting services. Additionally, SCM LifeScience operates in the cosmetics and hair growth protein manufacturing sectors. The company has 55 full-time employees. SCM LifeScience completed its initial public offering (IPO) on June 17, 2020. Its stock is listed under the ticker 298060.KQ on the Korean stock exchange, with an ISIN code of KR7298060005. The company's website is http://www.scmlifescience.com/. SCM LifeScience operates within the healthcare sector, specifically within the biotechnology industry. It does not provide details on its founding year, specific product names, or financial figures beyond the IPO date and employee count. The company's activities span drug development for stem cell therapy, cell production testing, and manufacturing of related products. SCM LifeScience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCM LifeScience Co stock

Net Debt to Free Cash Flow Ratio of SCM LifeScience Co is -0.16 in 2024.

Net Debt to Free Cash Flow Ratio of SCM LifeScience Co changed from 0.07 to -0.16, representing a -339.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio SCM LifeScience Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's SCM LifeScience Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SCM LifeScience Co

All Key Metrics — SCM LifeScience Co